The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
Subscribe To Our Newsletter & Stay Updated
